| 25113 | DABIGSO | Dabigatran Assay (1445SP) | Pradaxa | | | 22553 | D-DI | D-Dimer, Quantitative | | | | 25419 | GLIGA | Deamidated Gliadin IgA Antibodies | Sprue, Celiac, Deamidated Gliadin
| Deamidated Gliadin IgA Antibodies | | 25420 | GLIGG | Deamidated Gliadin IgG Antibodies | Sprue, Celiac, Deamidated Gliadin
| Deamidated Gliadin IgG Antibodies | | 23122 | DANDRSO | Dehydroepiandrosterone (DHEA_) | DHEA (Dehydroepiandrosterone) Unconjugated, DHEA(S), DHEA, Unconjugated | | | 22555 | DHEASO4 | Dehydroepiandrosterone Sulfate (DHEA-SO4) | DHEA-SO4
| | | 26426 | DNSAGSO | Dengue Virus NS1 Antigen, Serum (DNSAG) | Dengue Fever Break Bone Fever Flavivirus Mosquito-borne infection | DENS1 Dengue NS1 Ag, S DNAGI Dengue Ag Interpretation | | 26008 | DCPSO | Des-Gamma-Carboxy Prothrombin (DCP) | | | | 22558 | DESIPSO | Desipramine (DESPR) | Desipramine (Norpramin), Desipramine Serum, Norpramin (Desipramine), Norpramin (Desipramine) Serum, TCA (Tricyclic Antidepressants), Tricyclic Antidepressants (TCA) | | | 22559 | AM-CORT | Dexamethasone Suppression Test | Cortisol, AM | | | 26305 | MISC | Dexamethasone, Serum (500118) | Dexamethasone, Mass Spectromety | | | 26222 | DBS1SO | Diabetes Mellitus Type 1 Eval, Serum (DBS1) | Islet Cell autoantibodies | Diabetes Interp GAD65 Insulin IA-2 ZnT8 | | 22561 | DIAZSO | Diazepam and Nordiazepam (DIA) | Benzodiazepines, Clorazepate (Tranxene), Diazepam & Nordiazepam S, Diazepam (Valium), Nordiazepam (Tranxene), Tranxene (Clorazepate), Valium (Diazepam) | | | 22562 | DIC | DIC Profile | DIC, Disseminated Intravascular Coag. Profile | PT(INR), aPTT, Fibrinogen, D-dimer, Platelet count | | 22563 | DIF | Differential, Manual (WBC) Only | Diff, Peripheral Smear | Percent/absolute Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils, and any abnormal nucleated cells present, including blasts and NRBC's. RBC and platelet morphology also included. | | 22565 | DIGOX | Digoxin | Lanoxin, DIG, Digitalis | | | 23149 | MISC | Digoxin, Unbound, Serum or Plasma (191) | Digibind®; Lanoxicaps®; Lanoxin®, Digoxin, Free, Free Digoxin | | | 25046 | DIHYDSO | Dihydrotestosterone, Serum (DHTS) | 5-a-dihydrotestosterone, 5-Alpha-Dihydrotestosterone, Allodihydrotestosterone,
Androstanolone, DHT, Serum Dihydrotestosterone, Stanolone | | | 22566 | DRVVT | Dilute Russell Viper Venom Time | DRVVT | | | 23466 | DIPTESO | Diphtheria Tetanus Antibody Panel (DTABS) | Anti-tetanus toxoid, C. tetani, Clostridium tetani, Corynebacterium diphtheriae Antitoxin, Diphtheria Antitoxoid, Tetanus Immune Response, Tetanus toxoid antibodies, Tetanus/Diphtheria Antibody Panel Diphtheria/Tetanus Antibody Panel, Serum DTABSSO | Diphtheria Toxoid IgG Antibody
Tetanus Toxoid IgG Antibody | | 25071 | DIPGSO | Diphtheria Toxoid IgG (DIPGS) | Anti-diphtheria toxoid, Corynebacterium diphtheria, Diphtheria Immune Response, Diphtheria toxoid antibodies | | | 22567 | DAT | Direct Antiglobulin Test | Direct Coombs, DAT, Coombs Test, Direct
Direct Antiglobulin Test | | | 26488 | DSACSO | Disaccharidase Activity Panel, Tissue (DSAC) | Disaccharidase Determination | | | 22310 | DSDNA | Double Stranded DNA Antibodies | Anti-DNA, DNA antibodies, native DNA
| | | 22571 | DOXSO | Doxepin and Nordoxepin (DXPIN) | Adapin (Doxepin), Doxepin (Sinequan), Nordox (Doxepin) | | | 25599 | TOXIQL | Drug Evaluation, Comprehensive, Urine | Comprehensive drug screen, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, opiates, opioids, over-the counter, prescription, and illicit drugs.
| Test performed include:
1) Immunoassay presumptive screen for 11 drug classes, followed by quantitative confirmation by liquid chromatography methods (if needed)
2) Full-scan qualitative time-of-flight liquid chromatography mass spectrometry (LC-MS-QToF) to definitively detect a broad range of drugs that comprises
168 drugs and covers over 22 classes of over-the-counter, prescription, and illicit drugs encountered in our patient population. | | 26492 | METHSO | Drug Monitoring, Methamphetamine D/L Isomers, Urine (39413) | | d-Methamphetamine and l-Methamphetamine | | 23198 | MINDAS | Drug of Abuse Survey With Confirmation - Mini, Urine | Amphetamines, Cannabinoids, Cocaine, Opiates, Oxycodone, Marijuana, THC, Benzoylecgonine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxycontin, Vicodin, Amines
| Immunoassay screen plus mass-spectrometry method confirmation (when needed) for the following drug classes or method groups: amphetamines, cannabinoids, cocaine metabolite, opiate method group, and oxycodone method group. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen. | | 23197 | DAS | Drug of Abuse Survey With Confirmation, Urine | Amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol, Amines
DAU Survey with Confirmation. Drug. | Immunoassay screen with quantitative confirmation by liquid chromatography methods (when needed) for the following drug classes or method groups: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiate method group, oxycodone method group, and buprenorphine. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
Immunoassay screen for ethanol with quantitative result.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 26031 | DASWO | Drug of Abuse Survey without Confirmation, Urine | amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine
| Immunoassay screen for the following drug classes or method groups: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 25129 | BHDASWO | Drug of Abuse, Behav Hlth, Urine, Without Confirmation | amphetamines, benzodiazepines, cannabinoids, cocaine, opiates, oxycodone, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin
| Immunoassay screen for the following drug classes or method groups: amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, oxycodone. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 24944 | BHDAS | Drug of Abuse, Behavioral Health, Urine | amphetamines, benzodiazepines, cannabinoids, cocaine, opiates, oxycodone, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol, Amines
| Immunoassay screen quantitative confirmation by liquid chromatography methods (when needed) for the following drug classes or method groups: amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, and oxycodone method group. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 25062 | MEC10SO | Drug Screen 10 with Reflex Confirmation, Meconium (809313) | Amphetamines; Barbiturates; Benzodiazepines; Cocaine metabolite; Phencyclidine (PCP); Cannabinoids (THC metabolite); Opiates; Oxycodone; Methadone; Tramadol, MEC 10S0, Drug Screen 10, Meconium (809313) | Amphetamines, Barbiturates, Benzodiazepines, Cocaine metabolite, Opiates, Oxycodone, Phencyclidine (PCP), Cannabinoids (THC metabolite), Methadone, and Tramadol. Positive results are confirmed by or LC/MS-MS to limits of detection at no additional charge. | | 25080 | MEC4SO | Drug Screen 4 with Reflex Confirmation, Meconium (809173) | Amphetamines, Cannabinoids (THC Metabolite), Cocaine metabolite and Opiates, MEC C4SO, Drug Screen 4, Meconium (809173) | Panel includes: Amphetamines, Cannabinoids (THC Metabolite), Cocaine metabolite and Opiates. Positive results are confirmed by LC/MS-MS to limits of detection at no additional charge. | | 25081 | MEC5SO | Drug Screen 5 with Reflex Confirmation, Meconium (809566) | Amphetamines, Barbiturates, Cannabinoids (THC metabolite), Cocaine metabolite and Opiates, MEC C5SO, Drug Screen 5, Meconium (809566) | Panel includes: Amphetamines, Barbiturates, Cannabinoids (THC metabolite), Cocaine metabolite and Opiates. Positive results are confirmed by LC/MS/MS to limits of detection at no additional charge. | | 22198 | DRG-LIM | Drug Screen, Rapid Blood (ALC, ACETA, SAL) | Toxicology Screen, Blood - Stat, Drug Scn, Blood RAPID | Alcohol, Acetaminophen, and Salicylate | | 22572 | DRUGS | Drug Screen, Rapid Urine | Drug Screen, Rapid, Urine Only, Toxicology Screen, Stat, Urine Only, Drug Screen, Triage Urine, Drug Scn, Qual, Multi Urine | This rapid urine drug screen includes the following: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cannabinoids, Cocaine Metabolite, Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, and Tricyclic Antidepressants (TCAs). | | 22324 | APADRUG | Drug-Dependent Platelet Antibody (9000) | APA with drugs, Drug Dependent Platelet Antibody, Anti-Platelet Antibody with Drugs, APA-Drug Dependent, Anti-Platelet Ab., Drug dependent | | | 26149 | DYS2SO | Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum | ANNA (Antineuronal Nuclear Antibody), Anti-CV2, Anti-Enteric Neuronal Antibody, Anti-Hu, Antineuronal, Cerebellar Antibodies, Chorea, Collapsin Response-Mediator Protein-5 Antibody (CRMP-5), Serum, Cramp-fasciculation, CRMP-5, IgG, Dorsal Root Ganglion Antibody, DPPX, Hu Antibody, Isaacs disease, Motor End-Plate Antibody, Motor Nerve Terminal Antibodies, Myoid Antibody, Neuromuscular hyperexcitability, Neuromyotonia, Neuronal ganglionic acetylcholine receptor antibody, Neuronal Nuclear Antibody Panel, Neuronal Potassium Channel Ab, Neuronal-Anti, Paraneoplastic Antibodies, Paraneoplastic Autoantibody Evaluation, Paraneoplastic Neurological Autoimmunity, Stiff-man Syndrome, Potassium Channel Antibodies
|
If indirect immunofluorescence assay (IFA) patterns suggest collapsin response-mediator protein (CRMP)-5-IgG, then CRMP-5-IgG Western blot is performed at an additional charge. If IFA patterns suggest amphiphysin antibody, then amphiphysin antibody and/or amphiphysin immunoblot is performed at an additional charge. If IFA pattern suggests antineuronal nuclear antibodies (ANNA)-1 antibody, then ANNA-1 and ANNA-2 immunoblot is performed at an additional charge. If IFA pattern suggests Purkinje cytoplasmic antibody (PCA)-1 antibody, then PCA-1 immunoblot is performed at an additional charge. If IFA pattern suggests PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge. If IFA pattern suggests PCA type 1or type trace, then the appropriate antibody specific IFA is performed at an additional charge. If IFA pattern suggests N-methyl-D-aspartate (NMDA)-receptor, then NMDA-receptor cell-binding assay (CBA) and NMDA-receptor titer are performed at an additional charge. If IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptor, then AMPA-receptor CBA and AMPA-receptor titer are performed at an additional charge. If IFA pattern suggests gamma-aminobutyric acid B (GABA-B)-receptor, then GABA-B-receptor CBA and GABA-B-receptor titer are performed at an additional charge. If IFA pattern suggests dipeptidyl-peptidase-like protein-6 antibody (DPPX) antibody, then DPPX antibody CBA and DPPX titer are performed at an additional charge. |
|